Anavex Life Sciences Corp (AVXL)

[Gator328]

Here's what hangs me up a bit about the short thesis:

1. What incentive does Dr. Missling have to lie about the data? There's enough cash to run another trial and running a proper P3 trial is nothing to be ashamed of -- it's standard procedure. Dr. Missling is hoping that the current data is sufficient enough for a shot-on-goal attempt, but it's not like the FDA is going to permanently reject Blarcamesine based on this data. At worst it'll ask for more, and that's okay.

2. To that point, if the data were truly terrible, Dr. Missling would have immediately pivoted to one of the other pipeline drugs rather than spend runway cash hiring people whose expertise is more geared toward approval and commercialization.

And if our new FDA hires "just needed a job", why did they choose Anavex? It doesn't make sense to join a company that will be out of business/cash in a few years.